ClinicalTrials.gg

Program

claturafenib

Also written as “PF-07799933”, “PF-07799933 tablets with PF-07799544 fasted” and “PF-07799933 film-coated tablets with PF-07799544 fasted”.

In Pfizer's pipeline, BRAF Class 1 and Class 2 inhibitor. Its studies are mostly in Melanoma, led by Pfizer.

Furthest: phase 1, since Apr 26, 20222 company-led studies, 1 open or runningNext primary completion: Aug 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer21 open or runningphase 1since Apr 26, 2022Apr 26, 2022Aug 31, 2027phase 1 · NCT05355701
  • Named in Pfizer’s own pipeline as claturafenib PF-07799933, phase 1, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 26, 2022First study: phase 1 study in MelanomaFirst studyNCT05355701 · 103 enrolled · United States, Canada, Israel
  2. Apr 6, 2026Phase 1 study in HealthyNCT07563894 · 16 enrolled · United States

Ahead

  1. Aug 31, 2027Primary completion: phase 1 study in MelanomaNCT05355701

TargetBeta

“BRAF Class 1 and Class 2 inhibitor”the company's pipeline, read by Claude · source
“An orally bioavailable class 1 and 2 inhibitor of the serine/threonine-protein kinase B-raf (BRAF) protein, with potential antineoplastic activity. Upon oral administration, claturafenib selectively binds to and inhibits the activity of class 1 and 2 BRAF alterations. This inhibits the proliferat…”NCIt, read by Claude
“An orally bioavailable class 1 and 2 inhibitor of the serine/threonine-protein kinase B-raf (BRAF) protein, ”NCIt, by rule

Other programs on BRAF

ProgramCompanyFurthest phaseStudies
regorafenibruleBayerphase 440
tovorafenibruleday-one-biopharmaceuticals-incphase 38
BRAF V600E Inhibitor HLX208Fosun Pharmaphase 212
belvarafenibruleHanmi Pharmaceuticalphase 26

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07563894Healthy · United States1CompletedJun 24, 202616
NCT05355701Melanoma · United States, Canada, Israel1Active, not recruitingAug 31, 2027103

How it is read

Names in the registry

  • “PF-07799933”, 1 entry
  • “PF-07799933 tablets with PF-07799544 fasted”, 1 entry
  • “PF-07799933 film-coated tablets with PF-07799544 fasted”, 1 entry
  • “PF-07799933 film-coated tablets with PF-07799544 fed”, 1 entry
  • “PF-07799933 film-coated tablets fasted”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.